Aug 13 (Reuters) - Australia's CSL Ltd (CSL) reported a 15% jump in its full-year profit on Tuesday, on the back of strong growth in its core immunoglobulin business.
The biotech giant said its net profit after tax attributable for the year ended June 30 was $3.01 billion on a constant currency basis, higher than $2.86 billion from a year ago.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$198.37 |
Change
0.030(0.02%) |
Mkt cap ! $96.23B | |||
| Open | High | Low | Value | Volume |
| $200.98 | $203.69 | $198.37 | $647.4M | 3.086M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 428 | $198.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $198.40 | 360 | 2 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| CSL (ASX) Chart |